Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients

Next Previous
X
Search
Trial Profile

A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 882 (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors Arthrosi Therapeutics

    • Most Recent Events

    • 23 Aug 2024 According to an Arthrosi Therapeutics media release, additional positive data from a sub-population analysis for its Phase 2 clinical program in gout patients from the Asia-Pacific region are being presented as a poster at the 26th Asia-Pacific League of Associations for Rheumatology Congress, being held August 21-25 in Suntec, Singapore.
    • 15 Nov 2023 Results of an analysis reporting efficacy and safety based on various demographics and baseline characteristics following 12 weeks of treatment presented at the ACR Convergence 2023
    • 15 Nov 2023 Results assessing renal safety of AR882 uric acid excretion profiles across multiple studies (phase 1 studies and phase 2b) presented at the ACR Convergence 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top